Biotech firm Ignis raises $180m in Series A round led by 6 Dimensions

Ignis Therapeutics, a central nervous system (CNS)-focused biotech firm set up by SK Biopharmaceuticals in China, has raised $180 million in a Series A round of financing to bring the South Korean drug developer’s products to the world’s second-largest pharmaceutical market.

The Series A round was led by Shanghai-based 6 Dimensions Capital, which focuses on healthcare investments globally. Other participating investors include Ruentex Group, KB Investment, WTT investment, Mubadala Investment Company, HBM Healthcare Investments, and Goldman Sachs, according to a statement on Thursday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter